The conglomerate plans to bring $7 billion to $10 billion back on shore to invest in its U.S. operations and possibly buy “bolt-on” companies.
Should publicly held, early stage biotechs issue more shares or partner with Big Pharma?
With the right brand-value metrics and framework, managements can allocate marketing resources to improve both short- and long-term value creation.
But billionaire investor Sam Zell wonders when it was that BlackRock CEO Larry Fink “had been made God."
After May 25, 2018, companies found violating the General Data Protection Regulation are subject to fines of up to 4% of their annual worldwide…
Some of the most pressing issues boards of directors will face in 2018 are also the areas where they lack information or time to focus.
In "The Successful CFO," the author offers five focus areas for new CFOs and some “pearls of wisdom” for those who have been at the helm for…
How long will your budgeting process take this year?